Covid-19 pandemic: Keep using AstraZeneca vaccine, WHO urges world

"We urge countries to continue using this important Covid-19 vaccine," WHO Director General Tedros Adhanom Ghebreyesus told a news conference in Geneva.

AstraZeneca
European and British regulators also said this week that the benefits of AstraZeneca's shot outweighed the risks, prompting various nations to lift their suspensions | Photo: Reuters
Reuters
2 min read Last Updated : Mar 20 2021 | 2:58 AM IST
The World Health Organization (WHO) exhorted the world to keep administering AstraZeneca's Covid-19 shots on Friday, adding its endorsement to that of European and British regulators after concerns over blood clotting.
 
"We urge countries to continue using this important Covid-19 vaccine," WHO Director General Tedros Adhanom Ghebreyesus told a news conference in Geneva.
 
He was speaking after the global health body's vaccine safety panel said available data about the AstraZeneca shot did not point to any overall increase in clotting conditions.
 
European and British regulators also said this week that the benefits of AstraZeneca's shot outweighed the risks, prompting various nations to lift their suspensions.
 
"The AstraZeneca vaccine is especially important because it accounts for more than 90% of the vaccines being distributed through COVAX," Tedros added, referring to a WHO-led global vaccine-sharing scheme.
 
"There is no question. Covid-19 is a deadly disease, and the Oxford-AstraZeneca vaccine can prevent it. It's also important to remember that Covid-19 itself can cause blood clots and low platelets."
 
The WHO's global advisory committee on vaccine safety said in a statement that the AstraZeneca vaccine had a "positive benefit-risk profile" and "tremendous potential" to prevent infections and reduce deaths.
 
The WHO panel of 12 independent experts, who met virtually on Tuesday and on Thursday, reviewed safety data from Europe, the United Kingdom, India, and WHO's global database.
 
"While very rare and unique thromboembolic events in combination with thrombocytopenia, such as cerebral venous sinus thrombosis (CVST), have also been reported following vaccination with the AstraZeneca Covid-19 vaccine in Europe, it is not certain that they have been caused by vaccination," it said.
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirus VaccineAstraZenecaWorld Health Organization

Next Story